Vnitr Lek 2013, 59(3):209-213

Present and future of insulin treatment

J. Škrha
III. interní klinika 1. lékařské fakulty UK a VFN Praha, přednosta prof. MUDr. Štěpán Svačina, DrSc., MBA

The main goal of modern insulin treatment is to bring diabetes control to physiological regulation as close as possible. We move from human insulin to insulin analogues which may due to their properties reduce glucose excursions (glucose variability) with hypoglycemic and hyperglycemic episodes. Besides short acting insulin analogues diminishing extension of hyperinsulinemia and postprandial hypoglycemia observed by human insulin treatment, the long-acting analogues are used to create stabilized insulin level and to prevent nocturnal hypoglycemia. Individualized insulin treatment is the basement for modern trends in diabetology.

Keywords: human insulin; insulin analogues; individualized therapy

Received: January 28, 2013; Published: March 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Škrha J. Present and future of insulin treatment. Vnitr Lek. 2013;59(3):209-213.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Polak JF, Backlund JYC, Cleary PA et al. Progression of Carotid Artery Intima-Media Thickness During 12 Years in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes 2011; 60: 607-613. Go to original source... Go to PubMed...
    2. White NH, Sun WJ, Cleary PA et al. Effect of Prior Intensive Therapy in Type 1 Diabetes on 10-Year Progression of Retinopathy in the DCCT/EDIC: Comparison of Adults and Adolescents. Diabetes 2010; 59: 1244-1253. Go to original source... Go to PubMed...
    3. Ceriello A. The emerging challenge in diabetes: The "metabolic memory". Vascular Pharmacology 2012; 57: 133-138. Go to original source... Go to PubMed...
    4. Brazeau AS, Mircescu H, Desjardins K et al. Carbohydrate counting accuracy and blood glucose variability in adults with type 1 diabetes. Diabetes Research Clinical Practice 2013; 99: 19-23. Go to original source... Go to PubMed...
    5. Evans M, Schumm-Draeger PM, Vora J et al. A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations. Diabetes Obesity Metabolism 2011; 13: 677-684. Go to original source... Go to PubMed...
    6. Donner T, Munoz M. Update on Insulin Therapy for Type 2 Diabetes. J Clin Endocrinol Metab 2012; 97: 1405-1413. Go to original source... Go to PubMed...
    7. Keating GM. Insulin Detemir. A Review of its Use in the Management of Diabetes Mellitus. Drugs 2012; 72: 2255-2287. Go to original source... Go to PubMed...
    8. Pirags V, El Damassy H, Dabrowski M et al. Low risk of severe hypoglycaemia in patients with type 2 diabetes mellitus starting insulin therapy with premixed insulin analogues BID in outpatient settings. Int J Clin Pract 2012; 66: 1033-1041. Go to original source... Go to PubMed...
    9. Hompesch M, Muchmore DB, Morrow L et al. Improved Postprandial Glycemic Control in Patients with Type 2 Diabetes from Subcutaneous Injection of Insulin Lispro with Hyaluronidase. Diabetes Technol Therapeut 2012; 14: 218-224. Go to original source... Go to PubMed...
    10. Heinemann L. New ways of insulin delivery. Int J Clin Pract 2011; 65: (Suppl. 170) :31-46. Go to original source... Go to PubMed...
    11. Home PD, Meneghini L, Wendisch U et al. Improved health status with insulin degludec compared with insulin glargine in people with Type 1 diabetes. Diabetic Medicine 2012; 29: 716-720. Go to original source... Go to PubMed...
    12. Garber AJ, King AB, Del Prato S et al. Insulin degludec, an ultra-longlasting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012; 379: 1498-1507. Go to original source... Go to PubMed...
    13. Bergenstal RM, Rosenstock J, Arakaki RF et al. A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin-Treated Patients With Type 2 Diabetes. Diabetes Care 2012; 35: 2140-2147. Go to original source... Go to PubMed...
    14. Gonzales C, Maury E, Barcos I et al. Can Continuous Glucose Monitoring Systems Predict Glycemia? Diabetes Technology & Therapeutics 2012; 14: 1030-1032. Go to original source... Go to PubMed...
    15. Yang J, Sun H, Song C. Preparation, characterization and in vivo evaluation of pH-sensitive oral insulin-loaded poly(lactic-co-glycolicacid) nanoparticles. Diabetes Obesity & Metabolism 2012; 14: 358-364. Go to original source... Go to PubMed...
    16. Elleri D, Allen JM, Biagioni M et al. Evaluation of a portable ambulatory prototype for automated overnight closed-loop insulin delivery in young people with type 1 diabetes. Pediatric Diabetes 2012; 13: 449-453. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.